A Multi-Centered, Randomized, Two-Arm, Open Label Study to Evaluate Safety, Tolerability and Efficacy of Induction Treatment With Mitoxantrone Preceding Treatment With Glatiramer Acetate (Copaxone) Versus Chronic Treatment With Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis (MS).

Trial Profile

A Multi-Centered, Randomized, Two-Arm, Open Label Study to Evaluate Safety, Tolerability and Efficacy of Induction Treatment With Mitoxantrone Preceding Treatment With Glatiramer Acetate (Copaxone) Versus Chronic Treatment With Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis (MS).

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2011

At a glance

  • Drugs Glatiramer acetate; Mitoxantrone
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 04 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Apr 2010 Results presented at the 62nd Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top